

FOI030" 2502660






FIG. 1

2/22




Patient (1) - P1




Patient (2) - P1

FIG. 2


3/22



Tumor(1)



Tumor(2)



Tumor(3)

FIG. 3

4/22




FIG. 4

5/22

Patient(1)-P2




FIG. 5

6/22




FIG. 6

7/22




FIG. 7

8/22




FIG. 8

9/22




FIG. 9

10/22




FIG. 10

11/22




FIG. 11

12/22





FIG. 12

**Use of B38.1 antibody to direct
the infection of adenovirus to tumorigenic breast cancer cells**





**All cells tumorigenic
Targeting tumor**

**Breast cancer stem cells
Targeting subpopulation of cells**


FIG. 13

Cross-linking method to generate bi-specific antibodies



SHA2-Anti-Fiber

PDBA-Anti-B38.1



Bi-specific antibody

FIG. 14




FIG. 15




FIG. 16

Targeting of Adenovirus to different human cell lines




FIG. 17




FIG. 18




FIG. 19

20/22

 **Tumorigenic**
 **Non-Tumorigenic**




FIG. 20




FIG. 21




FIG. 22